| Literature DB >> 35795563 |
Wenwen Lin1,2, Yayong Luo1,2, Fang Liu1,2, Hangtian Li1,2, Qian Wang2, Zheyi Dong2, Xiangmei Chen1,2.
Abstract
Background: Diabetic nephropathy (DN) and diabetic retinopathy (DR) are microvascular complications of diabetes that share a similar pathogenesis and clinical relevance. The study aimed to visually analyze the research status and development trend of the relationship between DN and DR by means of bibliometrics and knowledge mapping.Entities:
Keywords: bibliometrics; citespace; diabetes; diabetic nephropathy; diabetic retinopathy
Year: 2022 PMID: 35795563 PMCID: PMC9251414 DOI: 10.3389/fphar.2022.937759
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Flow diagram of the publications screening process and bibliometric analysis methods.
FIGURE 2The number of annual publications on DN and DR research between 2000 and 2021. The horizontal coordinates represent the year of publication. The vertical coordinates represent the number of publications.
FIGURE 3(A) The collaboration network of countries. (B) Rose chart of the top 10 productive countries. (C) The collaboration network of institutions. (D) Rose chart of the top 10 productive institutions. (E) The collaboration network of authors. (F) Rose chart of the top 10 productive authors.
Top 10 publication counts and centralities of countries, institutions, and authors.
| Items | Rank | Count | Name | Rank | Centrality | Name |
|---|---|---|---|---|---|---|
| Country | 1 | 635 | United States | 1 | 0.32 | United States |
| 2 | 537 | China | 2 | 0.17 | Italy | |
| 3 | 292 | Japan | 3 | 0.14 | Australia | |
| 4 | 187 | England | 4 | 0.13 | England | |
| 5 | 186 | Italy | 5 | 0.08 | Saudi Arabia | |
| 6 | 183 | Australia | 6 | 0.08 | Malaysia | |
| 7 | 171 | India | 7 | 0.07 | Germany | |
| 8 | 165 | Germany | 8 | 0.06 | India | |
| 9 | 121 | Turkey | 9 | 0.06 | France | |
| 10 | 119 | Denmark | 10 | 0.05 | China | |
| Institution | 1 | 55 | Steno Diabet Ctr | 1 | 0.09 | Steno Diabet Ctr |
| 2 | 53 | Univ Melbourne | 2 | 0.09 | Harvard Univ | |
| 3 | 49 | Natl Univ Singapore | 3 | 0.09 | Univ Tokyo | |
| 4 | 44 | Univ Helsinki | 4 | 0.08 | Univ Melbourne | |
| 5 | 43 | Shanghai Jiao Tong Univ | 5 | 0.08 | Natl Univ Singapore | |
| 6 | 42 | Univ Sydney | 6 | 0.06 | Univ Toronto | |
| 7 | 39 | Univ Wisconsin | 7 | 0.05 | Univ Helsinki | |
| 8 | 31 | Monash Univ | 8 | 0.05 | Shanghai Jiao Tong Univ | |
| 9 | 30 | Univ Copenhagen | 9 | 0.05 | Tianjin Med Univ | |
| 10 | 26 | Harvard Univ | 10 | 0.04 | Univ Sydney | |
| Author | 1 | 37 | Tien Y. Wong | 1 | 0.01 | Tien Y. Wong |
| 2 | 34 | Ronald Klein | 2 | 0.01 | Ronald Klein | |
| 3 | 33 | Per-henrik Groop | 3 | 0.01 | Per-henrik Groop | |
| 4 | 31 | Hans-Henrik Parving | 4 | 0.01 | Hans-Henrik Parving | |
| 5 | 30 | Carol Forsblom | 5 | 0 | Carol Forsblom | |
| 6 | 20 | Charumathi Sabanayagam | 6 | 0 | Charumathi Sabanayagam | |
| 7 | 16 | Barbara E. K. Klein | 7 | 0 | Barbara E. K. Klein | |
| 8 | 15 | Lise Tarnow | 8 | 0 | Lise Tarnow | |
| 9 | 13 | FinnDiane Study Group | 9 | 0 | FinnDiane Study Group | |
| 10 | 11 | Daniel Gordin | 10 | 0 | Daniel Gordin |
FIGURE 4(A) The collaboration network of co-cited authors. (B) The collaboration network of co-cited journals.
Top 10 publication counts and centralities of co-cited authors and co-cited journals.
| Items | Rank | Count | Name | Rank | Centrality | Name |
|---|---|---|---|---|---|---|
| Co-cited author | 1 | 486 | Ronald Klein | 1 | 0.08 | Lloyd Paul Aiello |
| 2 | 471 | Harry Shamoon | 2 | 0.07 | Michael Brownlee | |
| 3 | 388 | Robert C. Turner | 3 | 0.07 | Hans-Henrik Parving | |
| 4 | 347 | Michael Brownlee | 4 | 0.07 | Paola Fioretto | |
| 5 | 308 | Andrew S. Levey | 5 | 0.06 | Antonio Ceriello | |
| 6 | 274 | American Diabetes Association | 6 | 0.05 | Robert C. Turner | |
| 7 | 264 | Hans-Henrik Parving | 7 | 0.05 | Andrzej S. Krolewski | |
| 8 | 240 | David M. Nathan | 8 | 0.05 | Hans-Peter Hammes | |
| 9 | 192 | Carl Erik Mogensen | 9 | 0.05 | Nish Chaturvedi | |
| 10 | 188 | Hertzel C. Gerstein | 10 | 0.05 | Trevor J. Orchard | |
| Co-cited journal | 1 | 2,517 | Diabetes Care | 1 | 0.05 | J. Cardiovasc. Pharm. |
| 2 | 2,102 | Diabetologia | 2 | 0.04 | Eur. J. Pharmacol. | |
| 3 | 2018 | Diabetes | 3 | 0.04 | Curr. Eye Res. | |
| 4 | 1698 | New Engl. J. Med. | 4 | 0.04 | Mol. Cell Biochem. | |
| 5 | 1393 | Diabetic Med. | 5 | 0.04 | Cancer Res. | |
| 6 | 1321 | Lancet | 6 | 0.03 | J. Intern. Med. | |
| 7 | 1260 | Diabetes Res. Clin. Pr. | 7 | 0.03 | Free Radical Bio. Med. | |
| 8 | 1246 | Kidney Int. | 8 | 0.03 | Endocrinology | |
| 9 | 1043 | JAMA | 9 | 0.03 | Febs. Lett. | |
| 10 | 932 | J. Am. Soc. Nephrol. | 10 | 0.03 | Brit. J. Pharmacol. |
FIGURE 5(A) The network of co-cited references. (B) The timeline view network of co-cited references. (C) The top 20 references with the strongest citation bursts.
Top 10 co-cited references.
| Rank | Frequency | Title | Author | Year | Journal |
|---|---|---|---|---|---|
| 1 | 64 | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) | Robert C. Turner | 1998 | Lancet |
| 2 | 52 | Global Prevalence and Major Risk Factors of Diabetic Retinopathy | Joanne W.Y. Yau | 2012 | Diabetes Care |
| 3 | 38 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 | M. R. Stearne | 1998 | BMJ |
| 4 | 38 | IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045 | N.H. Cho | 2018 | Diabetes Res. Clin. Pr. |
| 5 | 34 | Biochemistry and molecular cell biology of diabetic complications | Michael Brownlee | 2001 | Nature |
| 6 | 31 | Multifactorial Intervention and Cardiovascular Disease in patients with Type 2 Diabetes | Peter Gaede | 2003 | New Engl. J. Med. |
| 7 | 31 | Global aetiology and epidemiology of type 2 diabetes mellitus and its complications | Yan Zheng | 2018 | Nat. Rev. Endocrinol. |
| 8 | 30 | Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes | Anushka Patel | 2008 | New Engl. J. Med. |
| 9 | 30 | Effects of Intensive Glucose Lowering in Type 2 Diabetes | H.C. Gerstein | 2008 | New Engl. J. Med. |
| 10 | 29 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Barry M. Brenner | 2001 | New Engl. J. Med. |
Top 10 largest clusters of co-cited references.
| Cluster ID | Size | Silhouette | Mean year | Top terms (LLR) |
|---|---|---|---|---|
| #0 | 185 | 0.809 | 2015 | diabetes complications |
| #1 | 153 | 0.857 | 2007 | fenofibrate |
| #2 | 118 | 0.872 | 2011 | methylenetetrahydrofolate reductase |
| #3 | 109 | 0.89 | 2004 | microalbuminuria |
| #4 | 96 | 0.92 | 1998 | irbesartan |
| #5 | 93 | 0.954 | 1999 | carbonyl stress |
| #6 | 83 | 0.937 | 2017 | exosome |
| #7 | 81 | 0.917 | 2010 | chronic kidney disease |
| #8 | 73 | 0.928 | 2003 | ruboxistaurin |
| #9 | 62 | 0.95 | 2014 | renal biopsy |
FIGURE 6The alluvial flow map of co-cited references from 2017 to 2021.
FIGURE 7(A) The co-occurrence network of keywords. (B) The clusters of keywords. (C) The top 25 keywords with the strongest citation bursts.
Top 10 keywords by frequency and centrality.
| Rank | Count | Keyword | Centrality | Keyword |
|---|---|---|---|---|
| 1 | 1005 | diabetes mellitus | 0.05 | glycation end product |
| 2 | 785 | nephropathy | 0.05 | diagnosis |
| 3 | 727 | retinopathy | 0.05 | neuropathy |
| 4 | 552 | risk factor | 0.05 | insulin |
| 5 | 549 | diabetic retinopathy | 0.05 | follow up |
| 6 | 526 | type 2 diabetes mellitus | 0.04 | diabetic nephropathy |
| 7 | 507 | diabetic nephropathy | 0.04 | oxidative stress |
| 8 | 493 | prevalence | 0.04 | insulin resistance |
| 9 | 413 | disease | 0.04 | glomerular filtration rate |
| 10 | 410 | complication | 0.04 | coronary heart disease |
Top 6 largest clusters of keywords.
| Cluster ID | Silhouette | Mean year | Top terms (LLR) |
|---|---|---|---|
| 0 | 0.674 | 2007 | oxidative stress |
| 1 | 0.718 | 2005 | diabetic nephropathy |
| 2 | 0.59 | 2010 | glycemic control |
| 3 | 0.672 | 2009 | cardiovascular disease |
| 4 | 0.748 | 2008 | atherosclerosis risk |
| 5 | 0.98 | 2020 | machine learning |